News Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-07 EDT			5-day change	1st Jan Change
4.430 ^USD	-6.93%		+14.60%	-38.49%

06-30	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index	CI
06-30	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000 Value Index	CI

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT	03:59pm	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT	07-02	PR
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000 Value Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 2500 Value Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Value Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 2000 Value Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Microcap Value Index	06-29	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Value Benchmark	06-29	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Benchmark	06-29	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000 Value Benchmark	06-29	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 2500 Value Benchmark	06-29	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 2000 Value Benchmark	06-29	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Microcap Value Benchmark Index	06-29	CI
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT	06-27	PR
Altimmune, Inc. - Special Call	06-26
Altimmune shares slump as weight-loss drug's fatty liver trial data disappoints	06-26	RE
Altimmune Says Phase 2b Trial of Pemvidutide Shows 'Statistically Significant' MASH Resolution	06-26	MT
Altimmune's weight-loss drug meets main goal in fatty liver disease trial	06-26	RE
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH	06-26	AQ
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH	06-25	CI
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26	06-25	AQ
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	06-18	RE
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions	06-13	AQ
Altimmune, Inc., Q1 2025 Earnings Call, May 13, 2025	05-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Filters